Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High-dose Almonertinib(HS-10296) as First-line Treatment in Patients With EGFR-sensitive Mutations in Advanced NSCLC With Brain Metastases: Prospective, Open-label, Multi-center, Single-arm Clinical Trial

Next Previous
X
Search
Trial Profile

High-dose Almonertinib(HS-10296) as First-line Treatment in Patients With EGFR-sensitive Mutations in Advanced NSCLC With Brain Metastases: Prospective, Open-label, Multi-center, Single-arm Clinical Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aumolertinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ACHIEVE

    • Most Recent Events

    • 04 Jun 2024 Results(63 patients were selected and enrolled between Jul 6,2021 and Aug 31,2022) discussing Efficacy and biomarker analysis of almonertinib in treatment-naive EGFR-mutated NSCLC with CNS metastases presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 19 Apr 2024 Planned primary completion date changed from 15 Mar 2024 to 15 Jun 2024.
    • 19 Apr 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top